ISTH Appoints a New CEO
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn:
“News: We’re excited to announce Vishakha K. Kumar, as the new Executive Director/CEO of the International Society on Thrombosis and Haemostasis!
With more than 15 years of leadership experience across non-profit medical associations, healthcare, corporate and philanthropic organizations, Dr. Kumar brings a wealth of expertise to guide the Society’s next chapter of global growth and impact.
Working closely with the ISTH Council and staff, Dr. Kumar will help advance the Society’s strategic priorities while strengthening its commitment to serving the global thrombosis and hemostasis community through science, education and collaboration.
‘I am honored to join the ISTH and serve a global community that is making an extraordinary impact on patient care through science, education and collaboration. I look forward to building on the Society’s strong foundation to expand our global reach and create new opportunities to support innovation and education.’ — Vishakha K. Kumar.
Please join us in welcoming Dr. Kumar to the ISTH as we look ahead to an exciting future for our global community!”
Other posts about International Society on Thrombosis and Haemostasison Hemostasis Today.
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A